Negative Regulation of Estrogen Receptor α Transactivation Functions by LIM Domain Only 4 Protein

Rajesh R. Singh, Christopher J. Barnes, Amjad H. Talukder, Suzanne A.W. Fuqua, and Rakesh Kumar

Abstract

LIM domain only 4 (LMO4), a member of the LIM-only family of transcriptional coregulatory proteins, consists of two LIM protein-protein interaction domains that enable it to function as a linker protein in multiprotein complexes. Here, we have identified estrogen receptor α (ERα) and its corepressor, metastasis tumor antigen 1 (MTA1), as two novel binding partners of LMO4. Interestingly, LMO4 exhibited binding with both ERα and MTA1 and existed as a complex with ERα, MTA1, and histone deacetylases (HDAC), implying that LMO4 was a component of the MTA1 corepressor complex. Consistent with this notion, LMO4 overexpression repressed ERα transactivation functions in an HDAC-dependent manner. Accordingly, silencing of endogenous LMO4 expression resulted in a significant increased recruitment of ERα to target gene chromatin, stimulation of ERα transactivation activity, and enhanced expression of ERα-regulated genes. These findings suggested that LMO4 was an integral part of the molecular machinery involved in the negative regulation of ERα transactivation function in breast cells. Because LMO4 is up-regulated in human breast cancers, repression of ERα transactivation functions by LMO4 might contribute to the process of breast cancer progression by allowing the development of ERα-negative phenotypes, leading to increased aggressiveness of breast cancer cells. (Cancer Res 2005; 65(22): 10594-601)

Introduction

The LIM-only subclass of LIM proteins is a family of nuclear transcription coregulators that are characterized by the exclusive presence of two tandem LIM domains and no other functional domains. Each LIM domain has two cysteine-rich zinc finger motifs that are involved in protein-protein interactions but have no direct DNA-binding properties (reviewed in refs. 1, 2). These proteins regulate gene transcription by functioning as "linker" or "scaffolding" proteins by virtue of their LIM domains and are involved in the formation of multiprotein complexes of DNA-binding factors and transcriptional regulatory proteins. Four members of the LIM-only family [LIM domain only 1 (LMO1) to LMO4] have been identified to date. These proteins have been shown to play important roles in cell fate determination, tissue patterning, and organ development. As might be expected, their deregulated expression has been implicated in oncogenesis. LMO1 and LMO2 genes were discovered as oncogenes and are deregulated in acute T-cell lymphocytic leukemia (3–5). LMO2 is an obligate regulator of hematopoiesis and angiogenesis (6, 7) and blocks the terminal differentiation of hematopoietic cells when overexpressed (8). LMO3 was discovered on the basis of sequence homology and nothing much was known regarding its biological and pathologic significance. Recently, it was found that LMO3 interacts with neural transcription factor HEN2 and functions as an oncogene in neuroblastoma, where the expression level of both LMO3 and HEN2 genes was high and associated with poor prognosis (9).

LMO4 was the latest addition to this family and isolated as an interacting protein of Ldb1/NLI/CLIM and also identified in an expression screen with autologous serum of breast cancer patients (10–13). It has 165 amino acid residues and shares only ~50% amino acid sequence homology with the LIM domain regions of LMO1, LMO2, and LMO3; thus, it is considered the most distant relative of the family (11). It has a very broad spectrum of expression in human tissue (13). In mice, targeted disruption of LMO4 led to defects in neural tube closure, sphenoid bone formation, and altered anterior-posterior patterning (14, 15), revealing its importance in cell patterning and embryogenesis. Its expression is developmentally regulated in the mammary gland and overexpression blocks the differentiation of mammary epithelial cells (16). LMO4 is overexpressed in 50% of primary breast tumors (16), in squamous cell carcinomas of the oral cavity (17), and in primary prostate cancer (18), implicating it as an oncogene. It has been identified as a binding partner and a participant in multiprotein complexes with several transcriptional regulatory proteins, such as HEN1, deformed epidermal autoregulatory factor 1 (DEAF1), and BRCA1 (10–16). HEN1 (also known as NSCL1/NHLH1) is a basic helix-loop-helix protein. It functions as a transcriptional activator important in hematopoiesis and is specifically expressed in the developing nervous system (19). LMO2 and LMO4 were found to be binding partners of HEN1 by yeast two-hybrid analysis, but LMO4 and not LMO2 was found to be a repressor of its transcriptional activating functions (20). LMO4 was found to physically interact with CtBP-interacting protein and the breast and ovarian tumor suppressor protein BRCA1 (21). This study showed that LMO4 represses BRCA1-mediated transcriptional activation in yeast and mammalian cells but the mechanism of repression was not established (21). LMO4 also interacts with the coregulatory proteins Clim-2/Ldb1/NI1 and DEAF1 in the same complex. DEAF1 is a DNA-binding protein that interacts with regulatory sequences and modulates transcriptional outcome (12).

Providing additional implication of the role of LMO4 in breast carcinogenesis, it was shown in a recent study that overexpression of LMO4 in mice under the control of the mouse mammary tumor virus induced mammary hyperplasia and mammary intraepithelial neoplasia in two transgenic strains (22).
Estrogen receptors (ER) are ligand-dependent transcription factors that control a variety of essential physiologic and developmental processes in humans. The nuclear receptors primarily regulate the initiation of transcription by directly binding to specific DNA sequences in the regulatory region of target genes called hormone response elements and recruiting diverse ancillary factors characterized as coregulators along with the basal transcriptional machinery (23). Ligand binding results in the dismissal of histone deacetylase (HDAC)–containing corepressor complexes and the concomitant recruitment of coactivator complexes. One of such corepressors of ERα is the metastasis tumor antigen 1 (MTA1), a component of nuclear remodeling complex (24). It functions by recruiting HDACs, which deacetylate histones and subsequently facilitate the compaction of chromatin and transcriptional repression.

In the present study, we have identified LMO4 as a potent repressor of transcriptional activity of ERα. We have also identified ERα and its corepressor protein, MTA1, as LMO4 binding partners and established that a multiprotein complex of LMO4, ERα, MTA1, and HDACs existed in vivo. LMO4 was found to be an important component of the MTA1 corepressor complex and to negatively regulate the expression of the endogenous ERα target genes in a physiologic setting. The potential implications of these regulatory interactions and a role for LMO4 in modulating ERα functions in breast cancer cells are presented.

Materials and Methods

Cell culture and reagents. Human breast cancer cells were cultured in DMEM/F-12 medium supplemented with 10% fetal bovine serum (FBS). For estrogen treatment experiments, cells were grown in dextran-charcoal–stripped medium containing 5% charcoal-stripped FBS. Antibodies against the T7 tag were from Bethyl Laboratories (Montgomery, TX); anti-ERα was from Chemicon Inc. (Pittsburgh, PA); and anti-MTA1, HDAC1, and HDAC2 were from Santa Cruz (Santa Cruz, CA). Antimouse and antirabbit horseradish peroxidase or alkaline phosphatase–conjugated antibodies were from Santa Cruz (Santa Cruz, CA). An equal volume of 50 mmol/L Tris-HCl (pH 7.5), 500 mmol/L NaCl, 100 mmol/L NaF, 200 mmol/L NaVO₅, 1 mmol/L phenylmethylsulfonyl fluoride, and protease inhibitor cocktail (Life Technologies, Gaithersburg, MD) for 15 minutes at 4°C, washed thrice in PBS, and then incubated with secondary antibodies conjugated with 546-Alexa (red) or 488-Alexa (green) from Molecular Probes (Eugene, OR). The DNA dye Topro-3 (Molecular Probes) was used for nuclear localization (blue). Confocal scanning analysis was done using an Olympus FV900 laser scanning confocal microscope in accordance with established methods using sequential laser excitation to minimize the possibility of fluorescence emission bleed through. Each image is a three-dimensional reconstructed stack of serial Z sections at the same cellular level and magnification. Colocalization of two proteins is shown yellow for red and green fluorescence.

Transfection and promoter assays. Cells were maintained in DMEM/F-12 (1:1) supplemented with 10% FCS. For reporter assays, the required plasmids were transiently transfected using FUGENE6 kit from Roche Biochemicals (Indianapolis, IN) as per instructions of the manufacturer. Cotransfections were done with β-galactosidase and luciferase assays were done using Luciferase assay kit (Promega).

RNA interference transfection and reverse transcription-PCR. RNA interference (RNAi) transfections were done using Oligofect-AMINE (Invitrogen) according to the protocol of the manufacturer. RNAi against LMO4 was purchased from Qiagen. A pool of four individual RNAi was used and the sequences have been provided below. Forty-eight hours after transfection to allow efficient silencing of the gene. Reverse transcription-PCR (RT-PCR) was done using Access RT-PCR kit (Promega) using specific primers shown below:

LMO4 RNAi 1: 5'-ACGUCUCGGUUAACACAAAAAU-3'.
LMO4 RNAi 2: 5'-CAUGAUCUUUGCAGAAGAUAU-3'.
LMO4 RNAi 3: 5'-CGCAGGGCAUUGUGGUGUACAUU-3'.
LMO4 RNAi 4: 5'-UCAUACAUCAGGGCUUAAUAU-3'.
LMO4: 5'-GGAGCCGTCTTCTGCTTATG-3' and 5'-ACGAGTTCACTCTGAGGAA-3'.
ps2: 5'-ATACATTACGCAGTCCTCCCA-3' and 5'-AAAGGTTGTGCTGATTGGCGG-3'.
Total progesterone receptor (PR): 5'-CAATGAAAGCAGCTAATGGA-3' and 5'-TGCTCTCCTGGCAATGATT-3'.
Glyceraldehyde-3-phosphate dehydrogenase (GAPDH): 5'-CCATCTTCCAGGGCGGATC-3' and 5'-CCTTCAAGGATTGAG-3'.

Chromatin immunoprecipitation assay. Homologous protein-DNA complexes were measured by chromatin immunoprecipitation (ChIP) using the ChIP-IT kit (Active Motif, Carlsbad, CA). The chromatin extract was sonicated and immunoprecipitated using antibodies against ERα and MTA1. ChIP DNA was purified and resolved on a 10% SDS-PAGE gel, transferred to nitrocellulose membrane, and probed with appropriate antibodies.

Immunofluorescence and confocal microscopy studies. We determined the cellular localization of proteins by indirect immunofluorescence as described (24). Briefly, cells grown on glass coverslips were fixed in 4% phosphate-buffered paraformaldehyde for 15 minutes. Cells were permeabilized in methanol at −20°C for 4 minutes. Following permeabilization, cells were incubated with primary antibodies for 2 hours at room temperature, washed thrice in PBS, and then incubated with secondary antibodies conjugated with 546-Alexa (red) or 488-Alexa (green) from Molecular Probes (Eugene, OR). The DNA dye Topro-3 (Molecular Probes) was used for nuclear localization (blue). Confocal scanning analysis was done using an Olympus FV900 laser scanning confocal microscope in accordance with established methods using sequential laser excitation to minimize the possibility of fluorescence emission bleed through. Each image is a three-dimensional reconstructed stack of serial Z sections at the same cellular level and magnification. Colocalization of two proteins is shown yellow for red and green fluorescence.

LMO4 Regulation of ERα Functions

Transfection and promoter assays. Cells were maintained in DMEM/F-12 medium supplemented with 10% FCS. For reporter assays, the required plasmids were transiently transfected using FUGENE6 kit from Roche Biochemicals (Indianapolis, IN) as per instructions of the manufacturer. Cotransfections were done with β-galactosidase and luciferase assays were done using Luciferase assay kit (Promega).

RNA interference transfection and reverse transcription-PCR analysis. RNA interference (RNAi) transfections were done using Oligofect-AMINE (Invitrogen) according to the protocol of the manufacturer. RNAi against LMO4 was purchased from Qiagen. A pool of four individual RNAi was used and the sequences have been provided below. Forty-eight hours after transfection to allow efficient silencing of the gene. Reverse transcription-PCR (RT-PCR) was done using Access RT-PCR kit (Promega) using specific primers shown below:

LMO4 RNAi 1: 5'-ACGUCUCGGUUAACACAAAAAU-3'.
LMO4 RNAi 2: 5'-CAUGAUCUUUGCAGAAGAUAU-3'.
LMO4 RNAi 3: 5'-CGCAGGGCAUUGUGGUGUACAUU-3'.
LMO4 RNAi 4: 5'-UCAUACAUCAGGGCUUAAUAU-3'.
LMO4: 5'-GGAGCCGTCTTCTGCTTATG-3' and 5'-ACGAGTTCACTCTGAGGAA-3'.
ps2: 5'-ATACATTACGCAGTCCTCCCA-3' and 5'-AAAGGTTGTGCTGATTGGCGG-3'.
Total progesterone receptor (PR): 5'-CAATGAAAGCAGCTAATGGA-3' and 5'-TGCTCTCCTGGCAATGATT-3'.
Glyceraldehyde-3-phosphate dehydrogenase (GAPDH): 5'-CCATCTTCCAGGGCGGATC-3' and 5'-CCTTCAAGGATTGAG-3'.

Chromatin immunoprecipitation assay. Homologous protein-DNA complexes were measured by chromatin immunoprecipitation (ChIP) using the ChIP-IT kit (Active Motif, Carlsbad, CA). The chromatin extract was sonicated and immunoprecipitated using antibodies against ERα and MTA1. ChIP DNA was purified and resolved on a 10% SDS-PAGE gel, transferred to nitrocellulose membrane, and probed with appropriate antibodies.
Results

LIM domain only 4 represses estrogen receptor α transactivation activity. To gain insight into the functional role of dysregulated LMO4 in breast cancer, we decided to test the effect of LMO4 on ERE transactivation functions. First, we examined the effect of LMO4 overexpression on transcription from an estrogen response element (ERE)-luciferase reporter plasmid in two ERα-positive breast cancer cell lines, MCF-7 and ZR-75 (Fig. 1A and B). LMO4 overexpression in both cell lines led to a distinct repression of ERE transcription activity independent of estrogen stimulation, with a 3-fold repression in MCF-7 cells and a 2-fold repression in ZR-75 cells. To further validate the observed repression of ERE transactivation by LMO4, we examined the effects of increased amounts of LMO4 plasmid on ERE-luciferase transcription in transactivation by LMO4, we examined the effects of increased amounts of LMO4 plasmid on ERE-luciferase transcription in MCF-7 cells (Fig. 1C). As little as 250 ng of LMO4 was found to be sufficient to exert a potent repression of ER transactivation function in breast cancer cells and the extent of repression increased with increasing amount of LMO4 expression in the cells.

LIM domain only 4 represses estrogen receptor α transactivation in a histone deacetylase–dependent manner. To test the possibility that the repression of ERα functions by LMO4 could be HDAC dependent, we examined the effect of trichostatin A, a specific inhibitor of HDACs, on LMO4-induced repression of ERE transcription in both MCF-7 and ZR-75 cells (Fig. 2A). We found that LMO4-mediated repression of ERα transactivation activity could be effectively relieved by inhibiting HDAC activity. These results suggest that LMO4 requires functional HDACs for its noticed corepressor function of ERα function.

We have previously reported that MTA1, a component of the NURD complex, functioned as a corepressor of ERα transactivation functions by binding and recruiting HDACs to the repressor complex (24). To see if LMO4 may be functioning via this MTA1 corepressor complex, we tested the effect of silencing LMO4 expression using LMO4-specific RNAi on MTA1 repression of ERα transactivation function in MCF-7 cells. As expected, overexpression of MTA1 effectively repressed ERα transactivation functions (24), we next investigated the possibility that LMO4-corepressor complex, functioned as a corepressor of ERα and LMO4 were binding partners and strengthened the possibility that LMO4 could be a part of the MTA1 corepressor complex.

LIM domain only 4 also interacts with estrogen receptor α and histone deacetylase but not estrogen receptor β. Because LMO4 has been shown to be up-regulated in malignant breast cancers that were, in general, functionally ERα negative, and because MTA1 functions as a corepressor of ERα transcriptional functions (24), we next investigated the possibility that LMO4 directly interacted with ERα. Indeed, 35S-labeled ERα interacted with GST-tagged full-length LMO4 and its deletion constructs showed that the first LIM domain (LIM1, amino acids 20-89) of LMO4 was sufficient to bind 35S-labeled MTA1 (Fig. 3B, deletion construct B). Weak or no binding was observed between the MTA1 and the second LIM domain of LMO4. This bidirectional in vitro binding study showed that MTA1 and LMO4 were binding partners and strengthened the possibility that LMO4 could be a part of the MTA1 corepressor complex.

Figure 1. ERE-luciferase (ERE-Luc) activity was used as a functional assay to study the effect of LMO4 on ERE transcription in the cells. The expression construct (1 μg) for T7-tagged LMO4 was transiently transfected in MCF7 cells (A) and ZR-75 (B) breast cancer cells. Repression of estradiol (E2, 10^-9 mol/L)-mediated ERE transcription by 3-fold (MCF-7) and 2-fold (ZR-75) showed the repression of ERα transactivation functions by LMO4. C. increasing amounts of T7-LOM4 expression plasmid (250-1,000 ng with increments of 250 ng) were transfected in MCF-7 cells and a dose-dependent repression of ERE-transcription was observed. In all the assays, cells transfected with suitable vector (pcDNA) were used as controls for comparison. Columns, average of at least two separate experiments.

Cancer Research 2005; 65: (22). November 15, 2005 10596 www.aacrjournals.org

Downloaded from cancerres.aacrjournals.org on October 22, 2017. © 2005 American Association for Cancer Research.
amino acids 1-89) had binding affinity to Erα, whereas the second LIM domain had no appreciable binding affinity. Full-length 35S-labeled LMO4 was found to bind with the C domain (DNA-binding domain, amino acids 181-263) and the activation function 2 domain (domain E/AF-2, amino acids 301-552) of Erα with high affinity (Fig. 4B). No binding was observed with the activation function-1 domain (Fig. 3B, deletion constructs A and B, amino acids 1-180). We also tested the in vitro binding of LMO4 to HDAC2, which is an important component of the MTA1 corepressor complex (24). GST-tagged HDAC2 clearly showed binding affinity to 35S-labeled LMO4 in vitro (Fig. 4C). In addition to being a binding partner of Erα, we wanted to know whether LMO4 could also interact with Erβ. To address this question, we have done an in vitro binding experiment using 35S-labeled in vitro translated Erβ to GST-tagged full-length LMO4. No binding of LMO4 to Erβ was observed, indicating that LMO4 is likely a specific binding partner of Erα. The experiment was repeated twice for confirmation (Fig. 4D). Overall, this series of in vitro binding studies showed that LMO4 strongly interacts with the three integral components of the Erα-MTA1 corepressor complex, namely, Erα, MTA1, and HDACs.

LIM domain only 4 is a component of metastasis tumor antigen 1 corepressor complex. To confirm the binding of LMO4 with Erα and MTA1 in vivo, we did coimmunoprecipitation followed by Western blot analysis. Due to lack of a commercial antibody for LMO4 suitable for immunoprecipitation or Western immunoblotting of endogenous protein, we transfected MCF-7 cells with an expression vector of T7-tagged LMO4. Results indicate that immunoprecipitated T7-tagged LMO4 was present in the same multiprotein complex as Erα and MTA1 (Fig. 5A). Because MTA1 functions as a corepressor by recruiting HDACs (24), we next tested whether HDACs were also an integral part of the LMO4 and MTA1 complex. MCF-7 cells were transfected with Myc-tagged LMO4. Cell lysates were immunoprecipitated with anti-Myc antibody and analyzed for the presence of HDACs among the LMO4-associated endogenous proteins. Both HDAC1 and HDAC2 were immunoprecipitated along with LMO4 and MTA1 (Fig. 5B), demonstrating that LMO4 was a part of the MTA1 corepressor complex. These findings suggested that LMO4 may repress the Er transactivation function as an integral component of HDAC-containing corepressor complexes.

LIM domain only 4 colocalizes with metastasis tumor antigen 1 and estrogen receptor α in breast cancer cells. To confirm the protein-protein interactions between LMO4, MTA1, and Erα in situ, we next examined whether Myc-LMO4 colocalizes with the endogenous MTA1 and Erα in MCF-7 cells. Immunofluorescence studies indicated that LMO4 colocalizes individually with both MTA1 and Erα predominantly in the cell nucleus.
Overlap of red and green fluorescence resulted in the yellow spots (Fig. 5D and E, G and H), representing colocalization. Some LMO4 was also localized to the cytoplasm; however, such localization of LMO4 did not noticeably change in either serum-starved or estrogen-deprived MCF7 cells (data not shown). Together, these experiments confirmed MTA1 and ERα as new binding partners of LMO4.

**LIM domain only 4 is a natural inhibitor of endogenous estrogen receptor α functions.** To determine whether LMO4 could negatively regulate ERα transactivation functions in a physiologic context, we investigated changes in the expression level of the endogenous ERα target genes with knockdown of LMO4 expression in MCF-7 cells. Treatment of cells with LMO4-specific RNAi enhanced the level of pS2 mRNA by >2-fold when compared with cells treated with control RNAi (Fig. 6A, second panel). We also did RT-PCR analysis of another ER-regulated gene (i.e., PR) in cells transfected with control RNAi or LMO4-specific RNAi. Results indicate that RNAi-mediated down regulation of LMO4 expression increased total PR expression levels at least 2-fold (Fig. 6A, third panel). To further validate these results, we used Northern blot analysis of estrogen-responsive genes in MTA1-overexpressing stable cell lines. As expected from the earlier data, the expression levels in these stable clones were considerably repressed by overexpression of MTA1 when compared with the parental cells (24). Interestingly, knockdown of LMO4 expression led to a marked increase of pS2 mRNA levels (Fig. 6B). These data indicated that by decreasing the level of LMO4 expression, MTA1-induced repression of estrogen-responsive genes was relieved. Thus, LMO4 may be a functionally essential component of the MTA1 corepressor complex.

Silencing of LIM domain only 4 expression promotes estrogen receptor α recruitment to its target chromatin. To gain further insight into the observed negative regulatory function of LMO4 in relation to ERα-regulated genes, we next investigated whether the levels of the endogenous LMO4 also affected the recruitment of ERα to its target gene chromatin. To test this possibility, we examined the effect of silencing of LMO4 expression by LMO4 RNAi upon the ability of ERα to interact with the pS2 gene chromatin by chromatin immunoprecipitation assay in MCF-7 cells. On estrogen treatment, the level of recruitment of ERα to the pS2 gene chromatin was 2-fold higher in cells treated with LMO4 RNAi when compared with cells with control RNAi (Fig. 6C), clearly showing that silencing of LMO4 expression increased the recruitment of ER to its target genes. Together, these results clearly showed that LMO4 may be an endogenous regulator of ERα transactivation activity and functions in breast cancer cells, and up-regulation of LMO4 as has been observed in human breast cancer may lead to inhibition of ERα-transcriptional responsiveness.

**Discussion**

LMO4 is overexpressed in 50% of primary breast tumors and its enhanced expression blocks mammary gland differentiation. At the mechanistic level, very little is known regarding the mode of LMO4 functioning. LMO4 interacting molecular partners, or of the signaling pathways affected by LMO4 through which its effects in the breast cancer cells are manifested. In this context, we sought to investigate the effects of LMO4 upon estrogen signaling and functioning by focusing on key proteins of breast cancer tumorigenesis, such as the ERα and its coregulatory proteins. Preliminary ERE-luciferase assays conducted in MCF-7 and ZR-75 cell lines showed that LMO4 might be functioning as a negative regulator of ERα transactivation functions (Fig. 1). The LMO4-induced repression of ERE-luciferase could be reversed or relieved by trichostatin A, which is a specific inhibitor of HDACs (Fig. 2A) in both MCF-7 and ZR-75 cell lines. These data clearly showed that the repression exhibited by LMO4 was HDAC dependent. Studies on our laboratory had identified MTA1 as an ERα corepressor. MTA1 is a part of the NURD complex and functions by recruiting...
HDACs, which are a class of enzymes involved in deacetylation of hyperacetylated histone tails, leading to compaction of chromatin and transcriptional repression (25).

Because both LMO4 are MTA1 are predominantly nuclear coregulatory proteins, our results prompted us to check whether the repression of ERα by MTA1 and the repression by LMO4 were interrelated. Silencing of LMO4 repression resulted in the relieving of MTA1-induced repression of ERα functions (Fig. 2B) and silencing of MTA1 expression partially relieved LMO4-induced ERα repression (Fig. 2C). These data showed that the functions of these two proteins were interlinked and raised the possibility of LMO4 physically participating in the MTA1 corepressor complex. A series of different in vitro binding studies established that ERα, MTA1, and HDACs are novel binding partners of LMO4. The in vitro binding results were confirmed in vivo with T7-LMO4 interacting with both ERα and MTA1 (Fig. 5A). We also showed that transfected Myc-LMO4 could also be coimmunoprecipitated along with MTA1, HDAC1, and HDAC2 (Fig. 5B). Colocalization studies lent further support to the notion that LMO4 was a part of an MTA1 corepressor complex in vivo.

LIM domains are exclusively involved in protein-protein interactions. LMO4, with two tandem LIM domains with a capability of individually interacting with ERα, MTA1 and HDACs, may be playing the role of a “linker” or “scaffolding” protein involved in stabilizing the corepressor complex. In the same context, a recent study showed that LMO4 associated with glycoprotein 130 (gp130) subunit, a common receptor subunit for interleukin (IL)-6 type cytokines, and functioned as a part of the gp130 complex. Overexpression of LMO4 enhanced the transcription of IL-6 target genes like Stat3, whereas silencing of LMO4 expression by RNAi led to a decrease of transcription of IL-6 target genes, implying the function of LMO4 as a scaffolding protein in the stabilization of gp130 complex (26).

Silencing of LMO4 expression in cells with LMO4 RNAi led to a drastic increase of ERE transcription as measured by ERE-luciferase functional assay (Fig. 2) and this raised the possibility that LMO4 could act as a natural negative regulator of ERα pathway. Indeed, we discovered that down-regulation of LMO4 increased expression of estrogen-responsive genes pS2 and PR and also stimulated the recruitment of ERα to the endogenous pS2 gene chromatin (Fig. 6). Together, these findings established that LMO4 is a potent endogenous repressor of ERα transactivation function and that the levels of endogenous LMO4 may influence the status of ERα functions in breast cancer cells. In addition, there was also partial relieving of LMO4-induced repression of ERE transcription with MTA1 knockdown (Fig. 2C), suggesting the
possibility of potential involvement of additional corepressors in the noted corepressor function of LMO4. This, we believe, would open new avenues of study directed toward recognizing other ER-corepressor complexes of which LMO4 might be an integral part.

MTA1 is expressed virtually in all human cell lines and overexpressed in breast, ovarian, lung, gastric, colorectal, and pancreatic cancers. The level of MTA1 in rapidly growing breast cancer cells was found to be twice that in the normal epithelial cells (27). It functions as a part of HDAC or nucleosome remodeling complexes and acts as a major modulator of transcription. MTA1 was found to be a potent repressor of ERE transcription and overexpression of MTA1 in breast cancer cells enhanced the ability of cells to invade and grow in an anchorage-independent manner, implicating its role in metastatic potential of cells. Heregulin also promoted the interaction of MTA1 with ER (24). In addition, MTA1 expression could also be induced by the growth factor Heregulin, a ligand for HER3 and HER4, which is also frequently deregulated in human epithelial cancers (24). Indeed, breast cancer cell lines that highly express MTA1, such as MDA-MB-231 (29), BT474, and T47D (28), also express high levels of LMO4 (28). In addition, down-regulation of LMO4 expression in MDA-MB-231 cells, an invasive breast cancer cell line, resulted in 3- to 4-fold decrease in cell motility and a 2-fold decrease in cell invasion. Overexpression of LMO4 in MCF-10A, which is a normal breast epithelial cell line, resulted in a 3-fold increase in cell migration and 2-fold increase in cell invasion (22). Overexpression of MTA1 in MCF-7 breast cancer cell line also had an identical effect of increased cell invasiveness and anchorage-independent growth (24). Up-regulation of both MTA1 and LMO4 genes by a common signal (i.e., Heregulin) enhanced expression of these proteins in common breast cancer cell lines. Similar phenotypic changes resulting from overexpression all strongly support the notion of functional synergy between MTA1 and LMO4.

To summarize, in the present study, we have identified ERα and MTA1 as two novel binding partners of LMO4 in a physiologically relevant context and that LMO4 functions as an integral part of the MTA1 corepressor complex. LMO4 effectively repressed ERα transactivation functions in an HDAC-dependent manner. Down-regulation of LMO4 expression resulted in a significant enhancement of ERα functions. Because LMO4 is overexpressed in 50% of breast tumors and not much is known regarding the mechanistic relevance of this context and that LMO4 functions as an integral part of the MTA1 corepressor complex. LMO4 effectively repressed ERα transactivation functions in an HDAC-dependent manner. Down-regulation of LMO4 expression resulted in a significant enhancement of ERα functions. Because LMO4 is overexpressed in 50% of breast tumors and not much is known regarding the mechanistic role played by it at the molecular level as an oncogenic protein,
our present findings raise the possibility that LMO4 up-regulation might contribute to the process of breast cancer progression by repressing ERα transactivation functions and, consequently, allowing the development of ERα-negative phenotypes, leading to increased aggressiveness and invasiveness of breast cancer cells.

Acknowledgments

References


Figure 6. Knockdown of LMO4 expression leads to increased expression of ER target genes and enhanced recruitment of ER to the target chromatin. A, expression of estradiol-responsive genes pS2 and PR were evident in cells with silenced LMO4 expression (second and third panels, right lane) compared with the control cells, indicating elevated levels of ERα transcription. A decreased level of LMO4 expression (first panel, right lane) shows the effective knockdown of LMO4 by the LMO4-RNAi. GAPDH control for both the RNA samples is shown below (fourth panel). B, LMO4 expression was silenced in MCF-1-overexpressing stable clones and Northern blotting for pS2 mRNA clearly showed elevated levels of pS2 mRNA (first panel). Effective silencing of LMO4 expression is shown in the middle panel by probing for LMO4 mRNA and actin control for the RNA samples is shown in the bottom panels for comparison. C, MCF-7 cells were transfected with LMO4-RNAi, chromatin immunoprecipitation analysis was done with ERα-specific antibody, and the recruitment of ER to one of its target gene pS2 was studied. Decreased LMO4 expression resulted in a 2-fold increased recruitment of ER to pS2 gene chromatin on estrogen stimulation compared with cells with intact LMO4 expression. Quantification of the recruitment of ER to pS2 chromatin is shown below for comparison. Quantification was done using the program ImageQuant version 5.1.
Negative Regulation of Estrogen Receptor α Transactivation Functions by LIM Domain Only 4 Protein

Rajesh R. Singh, Christopher J. Barnes, Amjad H. Talukder, et al.


Updated version
Access the most recent version of this article at:
http://cancerres.aacrjournals.org/content/65/22/10594

Cited articles
This article cites 29 articles, 15 of which you can access for free at:
http://cancerres.aacrjournals.org/content/65/22/10594.full#ref-list-1

Citing articles
This article has been cited by 11 HighWire-hosted articles. Access the articles at:
http://cancerres.aacrjournals.org/content/65/22/10594.full#related-urls

E-mail alerts
Sign up to receive free email-alerts related to this article or journal.

Reprints and Subscriptions
To order reprints of this article or to subscribe to the journal, contact the AACR Publications Department at pubs@aacr.org.

Permissions
To request permission to re-use all or part of this article, contact the AACR Publications Department at permissions@aacr.org.